Sunitinib Malate
SUTENT
Kinase Inhibitor
NADAC/unit
N/A
No Shortage
Tier 1: 75.4%
PA Req: 397.6%
8 Manufacturers
32 ANDAs
Sunitinib Malate targets specific kinase enzymes involved in cancer cell growth and proliferation.
Market Intelligence
2024-12-11 Class II Recall: AvKARE
2024-12-11 Class II Recall: AvKARE
2023-07-19 Class II Recall: Teva Pharmaceuticals USA Inc
Generic Manufacturers
CP PHARMACEUTICALS INTERNATIONAL CVDR REDDYS LABORATORIES LTDEUGIA PHARMA SPECIALITIES LTDFOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO LTDMSN LABORATORIES PRIVATE LTDMYLAN PHARMACEUTICALS INCNATCO PHARMA LTDSUN PHARMACEUTICAL INDUSTRIES LTDTEVA PHARMACEUTICALS USA
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.